Q4 2022 Results

Company overview Innovation: Pipeline overview Cardiovascular XXB750 - NPR1 agonist NCT05562934 (CXXB750B12201) Hypertension Indication Phase Phase 2b Patients 170 Primary Outcome Measures week 12 Arms Financial review Immunology 2023 priorities Innovation: Clinical trials Neuroscience Change from baseline in mean 24hr ambulatory systolic blood pressure at Intervention Arm 1 experimental: Dose 1 Arm 2 experimental: Dose 2 Arm 3 experimental: Dose 3 Arm 4 experimental: Dose 4 Arm 5 placebo comparator Resistant Hypertension Patients Target Patients Readout Milestone(s) 2024 Publication TBD Oncology Appendix Abbreviations Other 67 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation